Analysts Offer Predictions for Zoetis Inc’s FY2018 Earnings (ZTS)

Zoetis Inc (NYSE:ZTS) – Investment analysts at Gabelli boosted their FY2018 earnings per share (EPS) estimates for Zoetis in a note issued to investors on Friday, November 2nd. Gabelli analyst K. Kedra now expects that the company will post earnings of $3.10 per share for the year, up from their previous estimate of $3.05. Gabelli also issued estimates for Zoetis’ FY2020 earnings at $4.00 EPS and FY2022 earnings at $4.95 EPS.

Several other equities research analysts also recently commented on ZTS. Jefferies Financial Group set a $96.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, July 13th. Cantor Fitzgerald set a $98.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, July 27th. Bank of America upped their price target on shares of Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 30th. BMO Capital Markets restated a “hold” rating and issued a $82.00 price target on shares of Zoetis in a research report on Thursday, August 2nd. Finally, Morgan Stanley upped their price target on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $93.19.

Shares of NYSE:ZTS opened at $92.76 on Monday. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The company has a market capitalization of $44.70 billion, a P/E ratio of 38.65, a PEG ratio of 1.74 and a beta of 0.97. Zoetis has a 52 week low of $67.76 and a 52 week high of $96.57.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 1st. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same period in the prior year, the business earned $0.65 earnings per share. The business’s quarterly revenue was up 9.9% on a year-over-year basis.

Several institutional investors and hedge funds have recently made changes to their positions in the company. LSV Asset Management acquired a new position in shares of Zoetis during the 3rd quarter worth $1,681,000. ING Groep NV increased its stake in shares of Zoetis by 56.7% during the 3rd quarter. ING Groep NV now owns 81,164 shares of the company’s stock worth $7,431,000 after purchasing an additional 29,353 shares during the last quarter. McKinley Carter Wealth Services Inc. acquired a new position in shares of Zoetis during the 3rd quarter worth $262,000. Bessemer Group Inc. increased its stake in shares of Zoetis by 0.8% during the 3rd quarter. Bessemer Group Inc. now owns 3,488,095 shares of the company’s stock worth $319,370,000 after purchasing an additional 28,598 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of Zoetis by 16.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 63,077 shares of the company’s stock worth $5,775,000 after purchasing an additional 8,911 shares during the last quarter. Institutional investors own 89.68% of the company’s stock.

In other Zoetis news, CEO Juan Ramon Alaix sold 135,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total value of $12,359,250.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Catherine A. Knupp sold 46,816 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the completion of the transaction, the insider now owns 81,640 shares in the company, valued at approximately $7,416,177.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 200,201 shares of company stock worth $18,306,772. Company insiders own 0.35% of the company’s stock.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be paid a $0.126 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.50 annualized dividend and a yield of 0.54%. Zoetis’s dividend payout ratio is presently 20.83%.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Featured Article: What are earnings reports?

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply